Prosthetic Valve Endocarditis Caused by Staphylococcus epidermidis: Development of Rifampin Resistance During Vancomycin and Rifampin Therapy

Bruce Chamovitz, Richard Bryant, David N. Gilbert, Alan I. Hartstein

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Development of rifampin-resistant Staphylococcus epidermidis was documented in three patients receiving vancomycin and rifampin therapy for prosthetic valve endocarditis. The minimum inhibitory concentrations and minimum bactericidal concentrations of rifampin for the original three isolates were 0.4 μg/mL or less. Organisms cultured during relapse or prosthetic valve replacement had minimum inhibitory concentrations of rifampin that were 12.5, 50, and greater than 100 μg/mL, respectively. Surgical intervention was necessary in all patients. One died, and one required a second prosthetic valve placement. The patients were treated with vancomycin plus aminoglycoside following identification of rifampin resistance. These observations suggest that vancomycin and rifampin may not be adequate therapy for prosthetic valve endocarditis caused by S epidermidis.

Original languageEnglish (US)
Pages (from-to)2867-2868
Number of pages2
JournalJAMA - Journal of the American Medical Association
Volume253
Issue number19
DOIs
StatePublished - May 17 1985

Fingerprint

Vancomycin Resistance
Staphylococcus epidermidis
Rifampin
Endocarditis
Vancomycin
Microbial Sensitivity Tests
Therapeutics
Aminoglycosides
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prosthetic Valve Endocarditis Caused by Staphylococcus epidermidis : Development of Rifampin Resistance During Vancomycin and Rifampin Therapy. / Chamovitz, Bruce; Bryant, Richard; Gilbert, David N.; Hartstein, Alan I.

In: JAMA - Journal of the American Medical Association, Vol. 253, No. 19, 17.05.1985, p. 2867-2868.

Research output: Contribution to journalArticle

@article{032e9c24bb234034aba37715386e6656,
title = "Prosthetic Valve Endocarditis Caused by Staphylococcus epidermidis: Development of Rifampin Resistance During Vancomycin and Rifampin Therapy",
abstract = "Development of rifampin-resistant Staphylococcus epidermidis was documented in three patients receiving vancomycin and rifampin therapy for prosthetic valve endocarditis. The minimum inhibitory concentrations and minimum bactericidal concentrations of rifampin for the original three isolates were 0.4 μg/mL or less. Organisms cultured during relapse or prosthetic valve replacement had minimum inhibitory concentrations of rifampin that were 12.5, 50, and greater than 100 μg/mL, respectively. Surgical intervention was necessary in all patients. One died, and one required a second prosthetic valve placement. The patients were treated with vancomycin plus aminoglycoside following identification of rifampin resistance. These observations suggest that vancomycin and rifampin may not be adequate therapy for prosthetic valve endocarditis caused by S epidermidis.",
author = "Bruce Chamovitz and Richard Bryant and Gilbert, {David N.} and Hartstein, {Alan I.}",
year = "1985",
month = "5",
day = "17",
doi = "10.1001/jama.1985.03350430079030",
language = "English (US)",
volume = "253",
pages = "2867--2868",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "19",

}

TY - JOUR

T1 - Prosthetic Valve Endocarditis Caused by Staphylococcus epidermidis

T2 - Development of Rifampin Resistance During Vancomycin and Rifampin Therapy

AU - Chamovitz, Bruce

AU - Bryant, Richard

AU - Gilbert, David N.

AU - Hartstein, Alan I.

PY - 1985/5/17

Y1 - 1985/5/17

N2 - Development of rifampin-resistant Staphylococcus epidermidis was documented in three patients receiving vancomycin and rifampin therapy for prosthetic valve endocarditis. The minimum inhibitory concentrations and minimum bactericidal concentrations of rifampin for the original three isolates were 0.4 μg/mL or less. Organisms cultured during relapse or prosthetic valve replacement had minimum inhibitory concentrations of rifampin that were 12.5, 50, and greater than 100 μg/mL, respectively. Surgical intervention was necessary in all patients. One died, and one required a second prosthetic valve placement. The patients were treated with vancomycin plus aminoglycoside following identification of rifampin resistance. These observations suggest that vancomycin and rifampin may not be adequate therapy for prosthetic valve endocarditis caused by S epidermidis.

AB - Development of rifampin-resistant Staphylococcus epidermidis was documented in three patients receiving vancomycin and rifampin therapy for prosthetic valve endocarditis. The minimum inhibitory concentrations and minimum bactericidal concentrations of rifampin for the original three isolates were 0.4 μg/mL or less. Organisms cultured during relapse or prosthetic valve replacement had minimum inhibitory concentrations of rifampin that were 12.5, 50, and greater than 100 μg/mL, respectively. Surgical intervention was necessary in all patients. One died, and one required a second prosthetic valve placement. The patients were treated with vancomycin plus aminoglycoside following identification of rifampin resistance. These observations suggest that vancomycin and rifampin may not be adequate therapy for prosthetic valve endocarditis caused by S epidermidis.

UR - http://www.scopus.com/inward/record.url?scp=0021879025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021879025&partnerID=8YFLogxK

U2 - 10.1001/jama.1985.03350430079030

DO - 10.1001/jama.1985.03350430079030

M3 - Article

C2 - 3989962

AN - SCOPUS:0021879025

VL - 253

SP - 2867

EP - 2868

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 19

ER -